NAAG Sends Letter to USDOJ Condemning January 6 Violence at U.S. Capitol

We all just witnessed a very dark day in America. The events of January 6 represent a direct, physical challenge to the rule of law and our democratic republic itself. Together, we will continue to do our part to repair the damage done to institutions and build a more perfect union. As Americans, and those charged with enforcing the law, we must come together to condemn lawless violence, making clear that such actions will not be allowed to go unchecked.

Read More →

NAAG Supports Daniel’s Law

The Daniel Anderl Judicial Security and Privacy Act honors the memory of the son of Judge Esther Salas of the U.S. District Court for the District of New Jersey. Daniel was tragically killed on July 19, 2020, when an armed assailant—a deranged attorney who had appeared in a case before Judge Salas—appeared at her home and opened fire. Daniel was only 20. Judge Salas’s husband was also shot in the attack. 

Read More →

NAAG Urges Congress to Extend CARES Act Spending Deadline

With COVID-19 cases rising daily in much of the country and many states still under a health emergency declaration, we urge Congress to amend the CRF program to allow state and local governments to spend the funding at least until December 31, 2021.

Read More →

NAAG Urges Congress to Pass Safeguarding America’s First Responders Act

This legislation ensures that families of officers and first responders lost while fighting the pandemic do not face unnecessary barriers to benefits they have already been promised.

Read More →

Attorneys General Ask Congress to Fund Expanded Access to Broadband

We urge Congress to close the digital divide and help ensure that all Americans have home internet connectivity necessary to participate in telemedicine, teleschooling, and telework as part of any additional legislation that provides relief and recovery resources related to addressing the COVID-19 pandemic.

Read More →

NAAG Urges U.S. Department of Veterans Affairs to Reevaluate Changes to Claims Processing Policy

We urge the VA to postpone any change to this long-standing policy until the VA, VSOs and veterans can have more thorough discussions regarding the VA’s reasons for the change, the implications it will have on VSOs and veterans, and whether there are alternative solutions that do not call for complete elimination of this critical quality review.

Read More →

Attorneys General Urge Congress to Adopt Key Changes to the Victims of Crime Act (VOCA)

As state Attorneys General, we are often the administrators of grant funding, through our state compensation programs or otherwise, financed directly from the Fund. In order to ensure the predictability and sustainability of these critical funds, change must be enacted to support our states’ ability to effectively serve victims and survivors of crime for years to come.

Read More →

Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)

Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

Florida, et al. v. Nine West Group, Inc. and John Doe, 1-500, 80 F. Supp.2d 181 (S.D.N.Y. 2000); No. 00-CV-1707 (S.D.N.Y. Dec. 14, 2000)

Plaintiff States sought damages and injunctive relief, alleging that Nine West Group (Nine West) conspired with unnamed dealers to set the minimum resale price at
which retailers were permitted to sell women’s dress shoes to customers.

Read More →